06/06/2023
Our much anticipated 2023 Biopharma in China has been released.
With its position as the second largest healthcare market globally, China has solidified its status as a strategic and essential market for companies seeking global expansion. The rapid growth of the middle class in China has created a pressing demand for innovative medicines and cutting-edge medical technology solutions.
Our 2023 report provides a practical tool kit for foreign companies to complete cross-border healthcare deals with China-based investors and strategic partners. Not only does it provide an overview of the Chinese healthcare market, its unique development trajectory, dynamics, and future trends, but the report also highlights how Chinese biopharma and healthcare companies, in general, are evolving and increasingly shifting their focus towards Europe for investment and partnership deals.''
Our much anticipated 2023 Biopharma in China has been released. Â With its position as the second largest healthcare market globally, China has solidified its status as a strategic and essential market for companies seeking global expansion. The rapid growth of the middle class in China has create...